JP2025506143A5 - - Google Patents
Info
- Publication number
- JP2025506143A5 JP2025506143A5 JP2024547227A JP2024547227A JP2025506143A5 JP 2025506143 A5 JP2025506143 A5 JP 2025506143A5 JP 2024547227 A JP2024547227 A JP 2024547227A JP 2024547227 A JP2024547227 A JP 2024547227A JP 2025506143 A5 JP2025506143 A5 JP 2025506143A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263308485P | 2022-02-09 | 2022-02-09 | |
| US63/308,485 | 2022-02-09 | ||
| US202263425960P | 2022-11-16 | 2022-11-16 | |
| US63/425,960 | 2022-11-16 | ||
| PCT/US2023/062185 WO2023154730A2 (en) | 2022-02-09 | 2023-02-08 | Multispecific binding agents and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506143A JP2025506143A (ja) | 2025-03-07 |
| JP2025506143A5 true JP2025506143A5 (cg-RX-API-DMAC7.html) | 2026-02-13 |
Family
ID=87565080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547227A Pending JP2025506143A (ja) | 2022-02-09 | 2023-02-08 | 多重特異性結合性作用剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250197502A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4475886A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506143A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023219697A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243802A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023154730A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021322114A1 (en) * | 2020-08-04 | 2023-03-02 | Exelixis, Inc. | Multispecific binding agents and uses thereof |
| CA3187850A1 (en) | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
| EP4574844A1 (en) * | 2023-12-22 | 2025-06-25 | Numab Therapeutics AG | Multispecific antibodies having specificity for cd47 and pdl1 |
| IL328540A (en) * | 2023-12-22 | 2026-07-01 | Numab Therapeutics AG | Antibody binding complexes specific for LILRB2 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| EA039662B1 (ru) * | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| GB2596411B (en) * | 2018-10-29 | 2023-09-20 | Tigatx Inc | Compositions and methods comprising IgA antibody constructs |
| CA3166328A1 (en) * | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
-
2023
- 2023-02-08 EP EP23753606.5A patent/EP4475886A4/en active Pending
- 2023-02-08 US US18/836,677 patent/US20250197502A1/en active Pending
- 2023-02-08 AU AU2023219697A patent/AU2023219697A1/en active Pending
- 2023-02-08 WO PCT/US2023/062185 patent/WO2023154730A2/en not_active Ceased
- 2023-02-08 JP JP2024547227A patent/JP2025506143A/ja active Pending
- 2023-02-08 CA CA3243802A patent/CA3243802A1/en active Pending